Protagenic Therapeutics (PTIXW) Competitors $0.04 -0.02 (-33.33%) As of 09/12/2025 01:24 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock PTIXW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ARAV, ACABW, BFRIW, BTMDW, and BCTXWShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), ARAVIVE (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech ARAVIVE Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Protagenic Therapeutics (NASDAQ:PTIXW) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Which has better earnings & valuation, ATNFW or PTIXW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AProtagenic TherapeuticsN/AN/AN/AN/AN/A Is ATNFW or PTIXW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Protagenic Therapeutics N/A N/A N/A Does the media refer more to ATNFW or PTIXW? In the previous week, Protagenic Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Protagenic Therapeutics and 0 mentions for 180 Life Sciences. Protagenic Therapeutics' average media sentiment score of 1.89 beat 180 Life Sciences' score of 0.00 indicating that Protagenic Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Protagenic Therapeutics Very Positive SummaryProtagenic Therapeutics beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIXW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIXW vs. The Competition Export to ExcelMetricProtagenic TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$153.68M$5.84B$10.14BDividend YieldN/A3.78%5.68%4.60%P/E RatioN/A41.0875.4125.98Price / SalesN/A4,942.15515.81181.13Price / CashN/A13.1937.5660.44Price / BookN/A103.7512.156.29Net IncomeN/A-$90.99M$3.29B$271.07M7 Day PerformanceN/A2.86%0.73%3.87%1 Month PerformanceN/A21.20%4.99%5.49%1 Year PerformanceN/A526.77%62.53%25.86% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXWProtagenic TherapeuticsN/A$0.04-33.3%N/AN/A$0.00N/A0.002Positive NewsGap DownATNFW180 Life SciencesN/A$0.19-10.4%N/A+1,189.8%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.00flatN/AN/A$0.00N/A0.002AIMDWAinosN/A$0.20-8.9%N/AN/A$0.00$110.87K0.0040Positive NewsGap DownALVOWAlvotechN/A$1.15+7.5%N/A-62.4%$0.00$560.10M0.004News CoverageGap DownHigh Trading VolumeARAVARAVIVEN/A$0.04flatN/AN/A$0.00$9.14M0.0020High Trading VolumeACABWAtlantic Coastal Acquisition Corp. IIN/A$0.05flatN/AN/A$0.00N/A0.0015BFRIWBiofronteraN/A$0.10-26.4%N/AN/A$0.00$39.19M0.0070Gap UpBTMDWbioteN/A$0.01-2.4%N/AN/A$0.00$199.07M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.03+19.0%N/A-84.4%$0.00N/A0.008Short Interest ↑Gap Down Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ARAV Competitors ACABW Competitors BFRIW Competitors BTMDW Competitors BCTXW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTIXW) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.